Scientists believe they may have found the “trigger” behind the extremely rare blood clotting complications resulting from the Oxford AstraZeneca vaccine.
According to an international team of researchers from Cardiff and the US, the reaction can be traced to how the adenovirus used by the vaccine binds with a specific protein in the blood to transfer the genetic material of the coronavirus into cells, called platelets. Known as Factor 4. (PF4).
Researchers believe this may trigger a chain reaction in the immune system that may result in the development of blood clots – a condition known as vaccine-induced immune thrombotic thrombocytopenia (VITT). goes.
Professor Alan Parker, from Cardiff University’s School of Medicine, said: “VITT only occurs in extremely rare cases because a series of complex events are required to trigger this ultra-rare side effect.
“Our data confirm that PF4 can bind to adenovirus, an important step in unraveling the underlying mechanism of VITT. Establishing a mechanism may help prevent and treat this disorder.
“We hope that our findings can be used to better understand the rare side effects of these new vaccines – and potentially to design new and better vaccines to turn the tide on this global pandemic, ” They said.
Scientists from AstraZeneca also participated in the research, which was published in the journal Science Advances.
A spokesperson for the company told the BBC: “While the research is not definitive, it provides interesting insights and AstraZeneca is exploring ways to take advantage of these findings as part of our efforts to address this extremely rare side effect. “
Credit: www.independent.co.uk /